To assess the duration of severe neutropenia in cycle 1 of chemotherapy after treatment with a single injection of KRN125 or multiple daily injections of filgrastim.

Inclusion Criteria:

• patients diagnosed as malignant lymphoma
• patients who were refractory to anthracycline or anthraquinone containing chemotherapy
• patients who are going to receive ESHAP or CHASE treatment regimen
• ECOG performance status =< 2
• patients who have appropriate bone marrow, hepatic and renal functions
• written informed consent

Exclusion Criteria:

• double cancer
• history of bone marrow transplantation or PBSCT
• more than 2 prior chemotherapy regimens
• primary hematologic disease such as myelodysplastic syndrome
• previous radiotherapy within 4 weeks of enrollment
• woman of childbearing potential who were either pregnant, breast feeding
• patients who participated in other clinical trials within the last 4 weeks of enrollment